[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100088621":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":67,"centralContacts":71,"locations":76,"responsibleParty":95,"collaborators":97,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":35,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":35,"enrollmentInfo":110,"targetDuration":35,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":35,"overallStatus":79,"whyStopped":35,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (cladribine and rituximab)","EXPERIMENTAL","Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.",[13,14,15],"Drug: Cladribine","Other: Laboratory Biomarker Analysis","Biological: Rituximab",[17,31,36],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Cladribine","Given IV",[9],[23,24,25,26,27,28,29,30],"2-CdA","2CDA","CdA","Cladribina","Leustat","Leustatin","Leustatine","RWJ-26251",{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Laboratory Biomarker Analysis","Correlative studies",[9],null,{"type":37,"name":38,"description":20,"armGroupLabels":39,"otherNames":40},"BIOLOGICAL","Rituximab",[9],[41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66],"ABP 798","BI 695500","C2B8 Monoclonal Antibody","Chimeric Anti-CD20 Antibody","CT-P10","IDEC-102","IDEC-C2B8","IDEC-C2B8 Monoclonal Antibody","MabThera","Monoclonal Antibody IDEC-C2B8","PF-05280586","Rituxan","Rituximab ABBS","Rituximab Biosimilar ABP 798","Rituximab Biosimilar BI 695500","Rituximab Biosimilar CT-P10","Rituximab Biosimilar GB241","Rituximab Biosimilar IBI301","Rituximab Biosimilar JHL1101","Rituximab Biosimilar PF-05280586","Rituximab Biosimilar RTXM83","Rituximab Biosimilar SAIT101","rituximab biosimilar TQB2303","rituximab-abbs","RTXM83","Truxima",[68],{"name":69,"affiliation":5,"role":70},"Farhad Ravandi-Kashani","PRINCIPAL_INVESTIGATOR",[72],{"name":69,"role":73,"phone":74,"phoneExt":35,"email":75},"CONTACT","713-792-7305","fravandi@mdanderson.org",[77],{"facility":78,"status":79,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":86,"coordinates":87},"Point",[88,89],-95.36327,29.76328,{"lat":89,"lon":88},[92,94],{"name":93,"role":73,"phone":74,"phoneExt":35,"email":75},"Farhad Ravandi-Kashani, MD",{"name":93,"role":70,"phone":35,"phoneExt":35,"email":35},{"type":96,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[98],{"name":99,"class":100},"National Cancer Institute (NCI)","NIH","100088621","phase-2-cladribine-and-rituximab-in-treating-patients-with-hairy-cell-leukemia-100088621",false,"NCT00412594","Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia","Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia","Inclusion Criteria:\n\n* Age 18 years and older\n* Diagnosis of hairy cell leukemia (HCL) established by bone marrow examination\n* Patients with relapsed disease are eligible if they have had no more than one prior therapy\n* Women of child-bearing potential must use birth control (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the study\n* Performance status =\\\u003C 3\n* Creatinine less than or equal to 2.0 unless related to the disease\n* Bilirubin less than or equal to 3.0\n* Transaminases less than or equal 3 x upper limit of normal unless related to the disease\n* No prior investigational agent in the 4 weeks prior to initiation of therapy\n\nExclusion Criteria:\n\n* Unable or unwilling to sign the consent form\n* Known infection with human immunodeficiency virus (HIV), hepatitis B or C\n* Presence of active infection\n* Presence of central nervous system (CNS) metastases\n* New York Heart Association classification III or IV heart disease\n* Prior chemotherapy (last 4 weeks)","ALL","18 Years",{"count":111,"type":112},150,"ESTIMATED","INTERVENTIONAL",[115],"PHASE2","This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.",[118,119],"Hairy Cell Leukemia","Recurrent Hairy Cell Leukemia","2026-06-09",{"date":122,"type":123},"2026-06-11","ACTUAL",{"date":125,"type":123},"2004-06-10",{"date":127,"type":112},"2027-06-30",{"name":5,"class":6},1]